This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Arcus Biosciences (RCUS) and Solventum Corporation (SOLV)

Tipranks - Tipranks - Wed Aug 12, 7:52AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haleon PLC Sponsored ADR (HLN), Arcus Biosciences (RCUS) and Solventum Corporation (SOLV).

Claim 55% Off TipRanks

Haleon PLC Sponsored ADR (HLN)

Argus Research analyst Taylor Conrad maintained a Buy rating on Haleon PLC Sponsored ADR yesterday and set a price target of $11.00. The company’s shares closed last Monday at $9.93.

According to TipRanks.com, Conrad is a 4-star analyst with an average return of 9.1% and a 61.0% success rate. Conrad covers the Consumer Goods sector, focusing on stocks such as Colgate-Palmolive, Church & Dwight, and Kimberly Clark. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Haleon PLC Sponsored ADR with a $8.61 average price target, which is a -12.9% downside from current levels. In a report issued on August 6, TipRanks – DeepSeek also upgraded the stock to Buy with a $11.00 price target.

See the top stocks recommended by analysts >>

Arcus Biosciences (RCUS)

Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on Arcus Biosciences today and set a price target of $29.00. The company’s shares closed last Monday at $28.72.

According to TipRanks.com, Zemansky is a 5-star analyst with an average return of 21.6% and a 60.2% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Eikon Therapeutics, Inc., Madrigal Pharmaceuticals, and Inhibikase Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcus Biosciences with a $38.44 average price target, which is a 35.4% upside from current levels. In a report issued on July 28, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $29.00 price target.

Solventum Corporation (SOLV)

Bank of America Securities analyst Travis Steed maintained a Hold rating on Solventum Corporation today and set a price target of $95.00. The company’s shares closed last Monday at $85.21, close to its 52-week high of $85.92.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 2.8% and a 52.9% success rate. Steed covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Inspire Medical Systems. ;'>

Solventum Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $98.50, representing a 19.7% upside. In a report issued on August 6, TipRanks – DeepSeek also downgraded the stock to Hold with a $95.00 price target.

Read More on HLN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).